Featured Posters & Presentations
Lyfgenia
Improvements in health-related quality of life for patients treated with LentiGlobin for sickle cell disease (bb1111) gene therapy.
Authors: Kanter JA.
Lyfgenia
Resolution of Serious Vaso-Occlusive Pain Crises and Reduction in Patient-Reported Pain Intensity: Results from the Ongoing Phase 1/2 HGB-206 Group C Study of LentiGlobin for Sickle Cell Disease (bb1111) Gene Therapy.
Authors: Thompson AA.
Zynteglo
Response of patients with transfusion-dependent β-thalassemia (TDT) to betibeglogene autotemcel (beti-cel; LentiGlobin for β-thalassemia) gene therapy based on HBB genotype and disease genetic modifiers.
Authors: Walters MC.
Zynteglo
Favorable outcomes in pediatric patients in the phase 3 Hgb-207 (Northstar-2) and Hgb-212 (Northstar-3) studies of betibeglogene autotemcel gene therapy for the treatment of transfusion-dependent β-thalassemia.
Authors: Thompson AA.
Zynteglo
Long-term efficacy and safety of betibeglogene autotemcel gene therapy for the treatment of transfusion-dependent β-thalassemia: results in patients with up to 6 years of follow-up.
Authors: Kwiatkowski JL.